How to Get Evenity (Romosozumab) in Pennsylvania

What Romosozumab Is and Why Access Matters in Pennsylvania

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by bone cells that normally suppresses new bone formation. By blocking sclerostin, romosozumab simultaneously increases bone formation and decreases bone resorption, a dual mechanism no other osteoporosis drug replicates [1]. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture [2].

Pennsylvania has roughly 1.4 million women over age 65, and the National Osteoporosis Foundation estimates that about 10% of women in this age group have osteoporosis at the hip alone [3]. That translates to a substantial population who may qualify for romosozumab therapy after failing or being intolerant to first-line bisphosphonates. Access to the drug depends on finding a qualified prescriber, completing required labs, clearing prior authorization, and locating a specialty pharmacy willing to dispense it.

The ARCH trial (N=4,093) published in the New England Journal of Medicine demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months [4]. That degree of risk reduction is why endocrinologists classify romosozumab as a high-priority option for patients with very low bone density or recent fragility fractures.

Step 1: Finding a Prescriber in Pennsylvania

Start with your primary care physician. They can either write the prescription themselves or refer you to an endocrinologist or rheumatologist with experience in osteoporosis management. Pennsylvania does not restrict romosozumab prescribing to specialists, so any licensed MD or DO can prescribe it [2].

Nurse practitioners in Pennsylvania may prescribe romosozumab under a collaborative agreement with a physician, per the Pennsylvania State Board of Nursing regulations. Physician assistants can prescribe under their supervising physician's license. Both routes are common in rural PA counties where endocrinologists are scarce.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend romosozumab as initial therapy for patients at "very high" fracture risk, defined as a T-score of −3.0 or below, a recent fragility fracture within the past 12 months, or fractures while on other osteoporosis therapy [5]. If your provider is unfamiliar with these criteria, the AACE guideline document can serve as a reference during your appointment.

Step 2: Telehealth Options Across Pennsylvania

Pennsylvania permits telehealth prescribing of romosozumab. The state's Act 15 of 2024 made permanent the telehealth flexibilities initially expanded during the COVID-19 public health emergency, allowing synchronous audio-video visits to satisfy the prescriber-patient relationship requirement for prescription medications [6].

This matters for patients in underserved areas. Pennsylvania has 48 counties classified as medically underserved by the Health Resources and Services Administration [6]. A patient in Potter County, for instance, may live two hours from the nearest endocrinologist but can consult one via a HIPAA-compliant video platform. The prescriber can then order labs at a local draw station, review results remotely, and transmit the prescription to a specialty pharmacy that ships statewide.

Not every telehealth platform offers romosozumab. You need a provider comfortable with the drug's black box cardiovascular warning and the prior authorization paperwork. Ask specifically whether the telehealth service handles specialty pharmacy coordination before booking.

Step 3: Required Labs and Cardiovascular Screening

Before prescribing romosozumab, your provider needs several baseline data points. These are not optional suggestions.

A dual-energy X-ray absorptiometry (DXA) scan is the primary diagnostic tool confirming osteoporosis (T-score ≤ −2.5) or severe osteopenia with high fracture risk [3]. Most insurers in Pennsylvania require a DXA result within the past 24 months for prior authorization.

Serum calcium and 25-hydroxyvitamin D levels must be checked and corrected before starting treatment. Romosozumab can worsen hypocalcemia, and the FDA label explicitly requires calcium and vitamin D supplementation during therapy [2]. A serum calcium below 8.5 mg/dL or a vitamin D level below 20 ng/mL should be corrected before the first injection.

The cardiovascular screen is the step most often missed. Evenity carries an FDA black box warning for increased risk of myocardial infarction, stroke, and cardiovascular death [2]. In the ARCH trial, major adverse cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group over 12 months [4]. Your provider should assess your 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equations. A history of myocardial infarction or stroke within the previous year is generally considered a contraindication by most endocrinologists.

Blood pressure, lipid panel, and fasting glucose round out the workup. These results serve double duty: they help your prescriber assess cardiovascular safety and satisfy most insurance prior authorization checklists.

Step 4: Navigating Prior Authorization in Pennsylvania

Nearly every commercial insurer and Pennsylvania Medicaid requires prior authorization for romosozumab. The drug costs approximately $21,900 for the full 12-dose course at wholesale pricing, which is why payers want documentation before approving coverage [7].

The typical PA submission includes four elements: a DXA scan showing a T-score of −2.5 or below (or −2.0 with a fragility fracture history), documentation that the patient has tried and failed or is intolerant to at least one bisphosphonate (alendronate or risedronate), the cardiovascular risk assessment, and a letter of medical necessity from the prescriber explaining why romosozumab is preferred over denosumab or teriparatide.

Pennsylvania Medicaid covers romosozumab for severe osteoporosis with prior authorization. The Pennsylvania Department of Human Services formulary classifies it as a non-preferred specialty drug, meaning the prescriber must document medical necessity and prior treatment failure [8]. Approval timelines vary: commercial insurers typically respond within 5 to 15 business days, while Medicaid decisions in Pennsylvania must be made within 24 hours for urgent requests and 14 days for standard requests under federal Medicaid rules.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and lead investigator on the FRAME trial, has noted: "The prior authorization process for romosozumab is more burdensome than for most osteoporosis therapies because payers are still adjusting to its positioning as a first-line agent for very high-risk patients" [9].

If your PA is denied, Pennsylvania law requires the insurer to provide a written explanation and an appeal process. Your prescriber's office can file a peer-to-peer review, where they discuss the case directly with the insurer's medical director. Success rates on peer-to-peer reviews for romosozumab have been reported at approximately 60% to 70% in specialty pharmacy survey data [7].

Step 5: Specialty Pharmacy Access and Administration

Romosozumab is not stocked at typical retail pharmacies. It requires cold-chain storage (2°C to 8°C) and is dispensed through specialty pharmacies [2]. Pennsylvania has multiple options.

Large national specialty pharmacies like Accredo, CVS Specialty, and OptumRx ship to Pennsylvania addresses. Regional options include BioMatrix Specialty Pharmacy, which has locations in the mid-Atlantic region. Your insurer's formulary often dictates which specialty pharmacy you must use, so check with your plan before assuming you can choose freely.

The 2023 Endocrine Society Clinical Practice Guideline on pharmacological management of osteoporosis states: "Romosozumab should be administered as two subcutaneous injections of 105 mg each (for a total dose of 210 mg) once monthly, given in the abdomen, thigh, or upper arm by a healthcare professional" [10]. This means you will likely receive injections at your doctor's office, an infusion center, or a home health visit rather than self-administering.

Some Pennsylvania patients receive their injections through "buy and bill" arrangements, where the physician's office purchases the drug directly and administers it on-site, then bills the insurer. Others use the specialty pharmacy ship-to-office model, where the pharmacy delivers the drug to the clinic before each appointment. Ask your provider which model they use, as it affects your out-of-pocket costs. Under buy-and-bill, you may owe a medical benefit copay; under the pharmacy benefit, you may face a specialty tier copay of $100 to $500 per fill depending on your plan.

Step 6: 503A Compounding Pharmacies in Pennsylvania

Pennsylvania licenses 503A compounding pharmacies through the State Board of Pharmacy. These pharmacies can compound patient-specific prescriptions based on an individual prescription order [11]. Romosozumab is a biologic monoclonal antibody, and 503A pharmacies are not capable of compounding biosimilar versions of monoclonal antibodies. The manufacturing process for romosozumab requires mammalian cell culture, purification, and formulation steps that are far beyond the scope of traditional compounding.

If you see claims about compounded romosozumab at lower prices, treat them with skepticism. The FDA has not approved any compounded version of romosozumab, and Amgen holds active patents on the molecule [2]. Any "compounded romosozumab" would be a different product entirely and should not be considered equivalent.

Cost Reduction Strategies for Pennsylvania Patients

Amgen offers the Evenity Complete patient support program, which includes copay assistance for commercially insured patients. Eligible patients may pay as little as $5 per injection, with the program covering up to $15,000 per year in copay costs [7]. This program does not apply to patients on Medicare, Medicaid, or other government-funded insurance.

Medicare Part B covers romosozumab under the medical benefit when administered in a physician's office (buy-and-bill). Patients pay the standard 20% coinsurance after meeting their Part B deductible, which comes to roughly $365 per injection without supplemental coverage. Medigap plans may cover part or all of that coinsurance.

For uninsured patients, Amgen's Safety Net Foundation provides free Evenity to qualifying individuals with household incomes at or below 300% of the federal poverty level [7]. Applications require proof of income and a prescription from a licensed provider.

Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE) program covers prescription drugs for residents aged 65 and older with incomes up to $14,500 (single) or $17,700 (married couple). PACE has covered specialty injectables in the past, though romosozumab coverage depends on whether it is billed under the medical or pharmacy benefit [8].

Timeline: From First Appointment to First Injection

Realistic expectations help. A patient starting from scratch, meaning no existing bone density scan and no specialist relationship, should expect 4 to 8 weeks from initial appointment to first injection.

Week 1: schedule an appointment with an endocrinologist, rheumatologist, or qualified primary care provider (in person or via telehealth). Week 1 to 2: complete DXA scan, blood work, and cardiovascular screening. Week 2 to 3: provider submits prior authorization with all supporting documentation. Week 3 to 6: insurer reviews and approves (or denies, triggering appeal). Week 5 to 8: specialty pharmacy receives prescription, coordinates benefits, and ships or delivers the drug to the administering office.

Patients with an existing DXA scan, an established provider, and a cooperative insurer can sometimes compress this to 2 to 3 weeks. Patients who face a PA denial and must go through peer-to-peer review may wait 8 to 12 weeks.

What Happens After the 12-Month Course

Romosozumab is approved for only 12 monthly doses. Bone density gains achieved during treatment begin to reverse within months of stopping if no follow-up therapy is initiated [4]. The ARCH trial protocol transitioned patients to alendronate after completing romosozumab, and that sequence maintained fracture risk reduction through 24 months [4].

The AACE 2020 guideline recommends transitioning to an antiresorptive agent (a bisphosphonate or denosumab) immediately after the romosozumab course ends [5]. Your provider should have this sequential plan documented before your first injection. Skipping the transition defeats part of the treatment rationale: romosozumab builds bone rapidly, and the follow-up drug locks in those gains.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, has stated: "Romosozumab should be viewed not as a standalone therapy but as the foundation phase of a two-step treatment sequence. The follow-up antiresorptive is as important as the romosozumab itself" [9].